SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) violated state or federal laws. ACADIA, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
On Wednesday, March 11, 2015, ACADIA announced that Uli Hacksell would retire immediately as both its CEO and a member of its board of directors. In another statement reported Wednesday, ACADIA announced that it would postpone the timing of its planned New Drug Application submission for Nuplazid to the second half of the year. The Company had originally planned to submit the application in the first quarter.
On this news, ACADIA stock during after market trading has been down over 20% on March 11, 2015.
If you are an ACADIA shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org) at 619-814-4471. If you email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.